Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Sasol Limited stock logo
SSL
Sasol
$7.92
-3.4%
$7.91
$7.10
$14.49
$5.02B2.42660,772 shs367,020 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$1.82
+6.4%
$2.04
$1.62
$5.70
$124.15M-0.36294,617 shs232,040 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Sasol Limited stock logo
SSL
Sasol
-3.41%-8.01%+3.39%-8.39%-38.65%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
+6.43%+1.11%-5.70%-22.22%-60.69%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Sasol Limited stock logo
SSL
Sasol
2.1122 of 5 stars
0.02.01.70.01.60.03.8
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.4171 of 5 stars
4.50.00.00.00.02.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Sasol Limited stock logo
SSL
Sasol
2.00
HoldN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
3.00
Buy$13.50641.76% Upside

Current Analyst Ratings

Latest PNS, VOR, DGH, SSL, and BWF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/22/2024
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$12.00
3/21/2024
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
3/21/2024
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$17.00 ➝ $15.00
3/21/2024
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00
3/21/2024
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.50
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Sasol Limited stock logo
SSL
Sasol
$16.30B0.31$4.30 per share1.84$17.92 per share0.44
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Sasol Limited stock logo
SSL
Sasol
$496.26MN/A0.002.700.33N/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/A-$1.76N/AN/AN/AN/AN/AN/A5/9/2024 (Estimated)

Latest PNS, VOR, DGH, SSL, and BWF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/20/2024Q4 2023
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
-$0.49-$0.39+$0.10-$0.39N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Sasol Limited stock logo
SSL
Sasol
$0.172.15%N/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A

Latest PNS, VOR, DGH, SSL, and BWF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/26/2024
Sasol Limited stock logo
SSL
Sasol
semi-annual$0.52486.9%3/14/20243/15/20243/29/2024
(Data available from 1/1/2013 forward)

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Sasol Limited stock logo
SSL
Sasol
1.21%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
Sasol Limited stock logo
SSL
Sasol
1.00%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
12.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Sasol Limited stock logo
SSL
Sasol
29,073634.34 million627.99 millionOptionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
16868.22 million54.30 millionNot Optionable

PNS, VOR, DGH, SSL, and BWF Headlines

SourceHeadline
TriLink BioTechnologies® kündigt neue Anlage in San Diego zur mRNA-Produktion von Arzneimittelwirkstoffen in der Spätphase anTriLink BioTechnologies® kündigt neue Anlage in San Diego zur mRNA-Produktion von Arzneimittelwirkstoffen in der Spätphase an
joplinglobe.com - April 20 at 8:41 PM
Vor Biopharma (NYSE:VOR) Trading Down 5.3%Vor Biopharma (NYSE:VOR) Trading Down 5.3%
americanbankingnews.com - April 16 at 1:52 AM
Buy Rating Affirmed for Vor Biopharma on Clinical Progress and Market PotentialBuy Rating Affirmed for Vor Biopharma on Clinical Progress and Market Potential
markets.businessinsider.com - April 13 at 12:43 AM
Seven diseases CRISPR technology could cureSeven diseases CRISPR technology could cure
labiotech.eu - April 4 at 7:22 PM
Why You Shouldnt Bet Against Vor Biopharma (VOR) StockWhy You Shouldn't Bet Against Vor Biopharma (VOR) Stock
zacks.com - April 4 at 9:36 AM
Vor Bio to Participate in Upcoming Investor ConferencesVor Bio to Participate in Upcoming Investor Conferences
globenewswire.com - April 1 at 8:00 AM
Heres Why Were Watching Vor Biopharmas (NASDAQ:VOR) Cash Burn SituationHere's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation
finance.yahoo.com - March 29 at 7:12 AM
The Penny Stock A-List: 7 High-Profile Companies on the Verge of GreatnessThe Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
investorplace.com - March 28 at 2:28 PM
Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)
markets.businessinsider.com - March 26 at 1:44 AM
Analysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)Analysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)
markets.businessinsider.com - March 22 at 3:59 PM
Vor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateVor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
finanznachrichten.de - March 22 at 5:21 AM
Analysts Have Conflicting Sentiments on These Healthcare Companies: LivaNova (LIVN), Vor Biopharma (VOR) and Neurogene (NGNE)Analysts Have Conflicting Sentiments on These Healthcare Companies: LivaNova (LIVN), Vor Biopharma (VOR) and Neurogene (NGNE)
markets.businessinsider.com - March 21 at 7:20 PM
Vor Biopharma: Q4 Earnings InsightsVor Biopharma: Q4 Earnings Insights
benzinga.com - March 20 at 9:49 PM
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results  and Provides Company UpdateVor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
finance.yahoo.com - March 20 at 4:49 PM
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company UpdateVor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
globenewswire.com - March 20 at 4:05 PM
Intellia Therapeutics doses first patient in pivotal in vivo CRISPR trialIntellia Therapeutics doses first patient in pivotal in vivo CRISPR trial
msn.com - March 19 at 5:15 PM
VOR Apr 2024 5.000 callVOR Apr 2024 5.000 call
finance.yahoo.com - March 16 at 11:47 PM
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - March 5 at 4:01 PM
Vor Bio to Participate in Upcoming Investor ConferencesVor Bio to Participate in Upcoming Investor Conferences
globenewswire.com - March 4 at 8:00 AM
Institutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the companyInstitutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the company
finance.yahoo.com - February 17 at 9:46 AM
2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)
finance.yahoo.com - February 15 at 5:49 PM
Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceVor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
finance.yahoo.com - February 7 at 4:09 PM
Personnel changes in the Exyte management: Mark Garvey and Elena Bashkeeva are welcomed as new members of the Executive BoardPersonnel changes in the Exyte management: Mark Garvey and Elena Bashkeeva are welcomed as new members of the Executive Board
finanznachrichten.de - February 5 at 12:31 PM
Vaxart spikes as B. Riley upgrades at long last after BARDA fundingVaxart spikes as B. Riley upgrades at long last after BARDA funding
msn.com - January 31 at 7:57 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Sasol logo

Sasol

NYSE:SSL
Sasol Limited operates as an integrated chemical and energy company in South Africa. It offers alumina, such as battery materials, catalyst supports, abrasives and polishing, and polymer additives; cobalt fischer-tropsch; carbon-based products; recarburiser; graphite electrodes; mono-ethylene glycol, ethylene, propylene, sasfroth blends, sodium cyanide, caustic soda, hydrochloric acid, sulfuric acid, calcium chloride, chlorine, alcohols, aromatic blends, methyl alcohol, polyethylene, polypropylene, polyvinyl chloride, cresols, xylenols, phenols, limestone ammonium nitrate, ammonium nitrate solution, and nitric acid. The company also provides linear alkyl benzene, sulfonate, fatty alcohols, alkoxylates, ether sulfates, solvents, dispersants, diluents esters, macrogol/PEG, AHA esters, waxes, dispersants, diluents, ethanol, isopropyl, acetone, MIBK and ethyl acetate, C6-C20+ and guerbet alcohols, ethoxylates, propoxylates, carboxylates, sulfates, sulfonates, LAS salts, paraffins, and ethylene oxide. In addition, it offers alcohols, esters, ethers, carboxylic acids, surfactants, oil and water soluble polyglycols, formulation and surface modifiers, solvents and coalescents, wax cuts, blends and forms, FT hard waxes, waxes and blends, lubrication packages, plasticizers, nucleators, release agents, emulsifiers, dispersants, wetting agents, tank-mix adjuvant components, fertiliser additives, specialty solvents, specialty grade acetone, MEK, various ethanol blends, n and i-propanol and butanol, various C4+ alcohols, ethyl and butyl acrylate monomers, octene, hexene, and pentene. Further, it explores, develops, produces, markets, and distributes natural oil and gas, and associated products; markets fuels and lubricants; develops lower-carbon energy solutions; operates coal mines; trades and transports oil, petrochemicals, and chemical products and derivatives; and provides engineering services. Sasol Limited was founded in 1950 and is based in Johannesburg, South Africa.
Vor Biopharma logo

Vor Biopharma

NYSE:VOR
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.